CellCentric Acquired | Healthcare M&A Deal

Venrock has completed the acquisition of CellCentric, a healthcare services other business in the United States, for $220 million. CellCentric is a biotechnology company developing inobrodib, an oral multiple myeloma medicine targeting p300 and CBP to suppress cancer-driving gene expression. The company is testing inobrodib in Phase 2 and plans a Phase 3 study, including all-oral combinations with Pomalyst and potential use alongside myeloma bispecific antibodies such as Elrexfio and Tecvayli, plus maintenance therapy. The Series D financing supports mid- and late-stage clinical development for persistent or relapsed disease, with the round positioned as healthcare M&A and other acquisition funding for a differentiated option.